Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.2.9078.8180
Address
Suite 506, Level 5 50 Clarence Street Sydney, New South Wales (NSW) 2000
Description
Bioxyne Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in United States of America (USA), and Asia. The Plant Based segment includes manufacturing, commercialization, and distribution of plant-based products. The Direct Sales segment focuses on Australia, and Asia operation. The company was founded in 1998 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.02
Trade Value (12mth)
AU$2,954.00
1 week
-7.69%
1 month
-7.69%
YTD
9.09%
1 year
0%
All time high
8.93
EPS 3 yr Growth
762.50%
EBITDA Margin
-15.00%
Operating Cashflow
-$4m
Free Cash Flow Return
-37.00%
ROIC
-133.10%
Interest Coverage
N/A
Quick Ratio
1.20
Shares on Issue (Fully Dilluted)
2047m
HALO Sector
Industrials
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
22 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
22 October 24 |
Letter to Shareholders re Notice of Annual General Meeting
×
Letter to Shareholders re Notice of Annual General Meeting |
17 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
17 October 24 |
Investor Presentation Update
×
Investor Presentation Update |
04 October 24 |
AGM Date and Director Nominations
×
AGM Date and Director Nominations |
30 September 24 |
Appendix 4G - Corporate Governance Statement
×
Appendix 4G - Corporate Governance Statement |
30 September 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
24 September 24 |
Bioxyne Extends Contract with Aura Therapeutics
×
Bioxyne Extends Contract with Aura Therapeutics |
24 September 24 |
Bioxyne Investor Webinar 25 September 2024
×
Bioxyne Investor Webinar 25 September 2024 |
18 September 24 |
Announcement 21.8.2024 Clarifying Statement
×
Announcement 21.8.2024 Clarifying Statement |
18 September 24 |
Reinstatement to Quotation
×
Reinstatement to Quotation |
18 September 24 |
Response to ASX Aware Query
×
Response to ASX Aware Query |
18 September 24 |
JMM Webinar Presentation
×
JMM Webinar Presentation |
13 September 24 |
Suspension from Official Quotation
×
Suspension from Official Quotation |
30 August 24 |
Preliminary Final Report
×
Preliminary Final Report |
23 August 24 |
Pause in Trading
×
Pause in Trading |
23 August 24 |
Response to ASX Query Letter
×
Response to ASX Query Letter |
21 August 24 |
BXN Manufactures First Pharmaceutical Cannabis Gummies
×
BXN Manufactures First Pharmaceutical Cannabis Gummies |
30 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
01 July 24 |
Addendum to Cy Biopharma Announcement 14.5.2024
×
Addendum to Cy Biopharma Announcement 14.5.2024 |
14 May 24 |
BXN Signs Collaboration Agreement with Cy Biopharma AG
×
BXN Signs Collaboration Agreement with Cy Biopharma AG |
13 May 24 |
Shares Out of Escrow
×
Shares Out of Escrow |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
22 April 24 |
Application for quotation of securities - BXN
×
Application for quotation of securities - BXN |
22 April 24 |
Cleansing Notice
×
Cleansing Notice |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.